- Business Wire•26 days ago
Avita Medical today issued the following CEO Shareholder Letter and Quarterly Report:
- Business Wire•last monthAvita Medical to Participate in the 3rd Annual Biotech and Money / Medtech and Money London 2017 Conference
Avita Medical Ltd , a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that Adam Kelliher, Avita’s Chief Executive Officer, will be a panel member at the Biotech and Money / Medtech and Money conference taking place in London, UK on 7-8 February, 2017.
- Marketwired•3 months agoPresentations at French Society of Plastic, Reconstructive and Aesthetic Surgery Reinforce Benefits of ReCell(R)
Avita Medical Ltd , a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that three presentations about the clinical benefits of its product ReCell® had ...
AVH.AX : Summary for AVITA MED FPO - Yahoo Finance
Avita Medical Limited (AVH.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.11 - 0.12|
|52 Week Range||0.09 - 0.15|
|PE Ratio (TTM)||-7.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|